Education
About Us
Working with TipRanks
Follow Us
Biosyent Inc (TSE:RX)
:RX
Total Valuation
Biosyent has a market cap or net worth of C$126.23M. The enterprise value is C$116.26M.
Market CapC$126.23M
Enterprise ValueC$116.26M
Share Statistics
Biosyent has 11,475,447 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,475,447
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biosyent’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 17.90%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.18
Return on Invested Capital (ROIC)17.90%
Return on Capital Employed (ROCE)0.24
Revenue Per Employee583.85K
Profits Per Employee121.17K
Employee Count60
Asset Turnover0.85
Inventory Turnover1.35
Valuation Ratios
The current PE Ratio of Biosyent is 15.1. Biosyent’s PEG ratio is 1.05.
PE Ratio15.1
PS Ratio3.64
PB Ratio3.64
Price to Fair Value3.64
Price to FCF31.91
Price to Operating Cash Flow10.19
PEG Ratio1.05
Income Statement
In the last 12 months, Biosyent had revenue of 35.03M and earned 7.27M in profits. Earnings per share was 0.63.
Revenue35.03M
Gross Profit27.86M
Operating Income8.75M
Pretax Income9.78M
Net Income7.27M
EBITDA10.43M
Earnings Per Share (EPS)0.63
Cash Flow
In the last 12 months, operating cash flow was 11.97M and capital expenditures -4.74M, giving a free cash flow of 7.23M billion.
Operating Cash Flow11.97M
Free Cash Flow7.23M
Free Cash Flow per Share0.63
Dividends & Yields
Biosyent pays an annual dividend of C$0.05, resulting in a dividend yield of 1.81%
Dividend Per ShareC$0.05
Dividend Yield1.81%
Payout Ratio26.00%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.41
52-Week Price Change-4.24%
50-Day Moving Average11.26
200-Day Moving Average11.26
Relative Strength Index (RSI)46.96
Average Volume (3m)5.67K
Important Dates
Biosyent upcoming earnings date is Mar 18, 2026, TBA (Confirmed).
Last Earnings DateNov 20, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend DateAug 29, 2025
Financial Position
Biosyent as a current ratio of 4.53, with Debt / Equity ratio of 2.51%
Current Ratio4.53
Quick Ratio3.54
Debt to Market Cap<0.01
Net Debt to EBITDA-1.06
Interest Coverage Ratio147.98
Taxes
In the past 12 months, Biosyent has paid 2.51M in taxes.
Income Tax2.51M
Effective Tax Rate0.26
Enterprise Valuation
Biosyent EV to EBITDA ratio is 11.16, with an EV/FCF ratio of 29.14.
EV to Sales3.32
EV to EBITDA11.16
EV to Free Cash Flow29.14
EV to Operating Cash Flow13.43
Balance Sheet
Biosyent has C$20.36M in cash and marketable securities with C$942.23K in debt, giving a net cash position of C$19.42M billion.
Cash & Marketable SecuritiesC$20.36M
Total DebtC$942.23K
Net CashC$19.42M
Net Cash Per ShareC$1.69
Tangible Book Value Per ShareC$2.59
Margins
Gross margin is 78.18%, with operating margin of 24.99%, and net profit margin of 20.75%.
Gross Margin78.18%
Operating Margin24.99%
Pretax Margin27.93%
Net Profit Margin20.75%
EBITDA Margin29.78%
EBIT Margin28.09%
Analyst Forecast
The average price target for Biosyent is C$13.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$13.50
Price Target Upside24.42% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast22.22%
EPS Growth Forecast25.50%